Press Releases

March 3, 2023
WALTHAM, Mass., March 03, 2023 (GLOBE NEWSWIRE) -- Morphic Therapeutic  (Nasdaq: MORF), a biotechnology company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that its management team will participate a panel discussion focused
February 14, 2023
WALTHAM, Mass., Feb. 14, 2023 (GLOBE NEWSWIRE) -- Morphic Therapeutic  (Nasdaq: MORF), a biotechnology company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that its management team will participate in the virtual SVB Leerink
Scroll to Top